OperaV1, PubMed, Curation, bibRecord, 000192

[OPERa Study].

Identifieur interne : 000192 ( PubMed/Curation ); précédent : 000191; suivant : 000193

[OPERa Study].

Auteurs : P. Tesa Ová

Source :

Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti [ 0862-495X ] ; 2013.

RBID : pubmed:24320592

English descriptors

KwdEn :
- Age Factors, Aged, Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Female, Fever (chemically induced), Fever (epidemiology), Fever (prevention & control), Granulocyte Colony-Stimulating Factor (therapeutic use), Humans, Incidence, Length of Stay, Male, Neoplasms (drug therapy), Neoplasms (immunology), Neutropenia (chemically induced), Neutropenia (epidemiology), Neutropenia (prevention & control), Practice Guidelines as Topic, Recombinant Proteins (therapeutic use), Risk Factors.
MESH :
- chemical , therapeutic use : Granulocyte Colony-Stimulating Factor, Recombinant Proteins.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols.
- chemically induced : Fever, Neutropenia.
- drug therapy : Neoplasms.
- epidemiology : Fever, Neutropenia.
- immunology : Neoplasms.
- prevention & control : Fever, Neutropenia.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Age Factors, Aged, Female, Humans, Incidence, Length of Stay, Male, Practice Guidelines as Topic, Risk Factors.

Abstract

On the whole, most European and international guidelines recommend prophylactic use of granulocyte-colony stimulating factors (G-CSFs) when the risk of chemotherapy-induced febrile neutropenia (FN) in cancer patients exceeds 20%. In patients treated with intermediate-risk chemotherapy regimens the recent EORTC guidelines recommend to consider supplementary patient-related adverse risk factors such as elderly age ( 65 years) prior to administrating each cycle of chemotherapy. The primary objective of our study is to describe the most important FN risk factors that underlie the use of pegfilgrastim PP in daily practice in the Czech Republic; secon-dary endpoints include FN incidence, chemotherapy dose intensity, anti-infective agents admini-stration, hospitalization length and safety of chemotherapy regimens.

PubMed: 24320592

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000192

Links to Exploration step

pubmed:24320592

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[OPERa Study].</title>
<author><name sortKey="Tesa Ova, P" sort="Tesa Ova, P" uniqKey="Tesa Ova P" first="P" last="Tesa Ová">P. Tesa Ová</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="RBID">pubmed:24320592</idno>
<idno type="pmid">24320592</idno>
<idno type="wicri:Area/PubMed/Corpus">000192</idno>
<idno type="wicri:Area/PubMed/Curation">000192</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[OPERa Study].</title>
<author><name sortKey="Tesa Ova, P" sort="Tesa Ova, P" uniqKey="Tesa Ova P" first="P" last="Tesa Ová">P. Tesa Ová</name>
</author>
</analytic>
<series><title level="j">Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti</title>
<idno type="ISSN">0862-495X</idno>
<imprint><date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors</term>
<term>Aged</term>
<term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term>
<term>Female</term>
<term>Fever (chemically induced)</term>
<term>Fever (epidemiology)</term>
<term>Fever (prevention & control)</term>
<term>Granulocyte Colony-Stimulating Factor (therapeutic use)</term>
<term>Humans</term>
<term>Incidence</term>
<term>Length of Stay</term>
<term>Male</term>
<term>Neoplasms (drug therapy)</term>
<term>Neoplasms (immunology)</term>
<term>Neutropenia (chemically induced)</term>
<term>Neutropenia (epidemiology)</term>
<term>Neutropenia (prevention & control)</term>
<term>Practice Guidelines as Topic</term>
<term>Recombinant Proteins (therapeutic use)</term>
<term>Risk Factors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Granulocyte Colony-Stimulating Factor</term>
<term>Recombinant Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Fever</term>
<term>Neutropenia</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Fever</term>
<term>Neutropenia</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Fever</term>
<term>Neutropenia</term>
</keywords>
<keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Age Factors</term>
<term>Aged</term>
<term>Female</term>
<term>Humans</term>
<term>Incidence</term>
<term>Length of Stay</term>
<term>Male</term>
<term>Practice Guidelines as Topic</term>
<term>Risk Factors</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">On the whole, most European and international guidelines recommend prophylactic use of granulocyte-colony stimulating factors (G-CSFs) when the risk of chemotherapy-induced febrile neutropenia (FN) in cancer patients exceeds 20%. In patients treated with intermediate-risk chemotherapy regimens the recent EORTC guidelines recommend to consider supplementary patient-related adverse risk factors such as elderly age ( 65 years) prior to administrating each cycle of chemotherapy. The primary objective of our study is to describe the most important FN risk factors that underlie the use of pegfilgrastim PP in daily practice in the Czech Republic; secon-dary endpoints include FN incidence, chemotherapy dose intensity, anti-infective agents admini-stration, hospitalization length and safety of chemotherapy regimens.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">24320592</PMID>
<DateCreated><Year>2013</Year>
<Month>12</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted><Year>2015</Year>
<Month>09</Month>
<Day>08</Day>
</DateCompleted>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0862-495X</ISSN>
<JournalIssue CitedMedium="Print"><Volume>26</Volume>
<Issue>6</Issue>
<PubDate><Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti</Title>
<ISOAbbreviation>Klin Onkol</ISOAbbreviation>
</Journal>
<ArticleTitle>[OPERa Study].</ArticleTitle>
<Pagination><MedlinePgn>425-33</MedlinePgn>
</Pagination>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">On the whole, most European and international guidelines recommend prophylactic use of granulocyte-colony stimulating factors (G-CSFs) when the risk of chemotherapy-induced febrile neutropenia (FN) in cancer patients exceeds 20%. In patients treated with intermediate-risk chemotherapy regimens the recent EORTC guidelines recommend to consider supplementary patient-related adverse risk factors such as elderly age ( 65 years) prior to administrating each cycle of chemotherapy. The primary objective of our study is to describe the most important FN risk factors that underlie the use of pegfilgrastim PP in daily practice in the Czech Republic; secon-dary endpoints include FN incidence, chemotherapy dose intensity, anti-infective agents admini-stration, hospitalization length and safety of chemotherapy regimens.</AbstractText>
<AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">This prospective, multicenter, non-interventional study enrolled patients receiving a chemotherapy with high FN risk ( 20% according to EORTC guidelines) based on investigators` assessment.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Data were collected on a total of 333 patients treated for breast cancer (69%), lymphoma (20%), ovarian (5%), lung (4%) and testicular cancer (1%). The most frequent indications for G-CSF prophylaxis were myelotoxic chemotherapy regimen (96%), elderly age (36%), advanced stage disease (35%), female gender (30%), cancer type (15%) and previous FN episode (12%). The overall FN incidence was 3% in patients receiving primary pegfilgrastim prophylaxis (n = 210) and 12% in patients with no pegfilgrastim PP (n = 123).</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The myelotoxicity of a chemotherapeutic regimen was the most significant FN risk factor identified by the inquired physicians. The second most compelling FN risk factor was elderly age and advanced stage disease. FN incidence in patients who received pegfilgrastim PP was relatively low in comparison to the commonly expected FN incidence in a population of patients receiving a chemotherapy regimen with high risk of FN.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tesařová</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
</AuthorList>
<Language>cze</Language>
<PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<VernacularTitle>Studie OPERa.</VernacularTitle>
</Article>
<MedlineJournalInfo><Country>Czech Republic</Country>
<MedlineTA>Klin Onkol</MedlineTA>
<NlmUniqueID>9425213</NlmUniqueID>
<ISSNLinking>0862-495X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>143011-72-7</RegistryNumber>
<NameOfSubstance UI="D016179">Granulocyte Colony-Stimulating Factor</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>3A58010674</RegistryNumber>
<NameOfSubstance UI="C455861">pegfilgrastim</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000367">Age Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005334">Fever</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016179">Granulocyte Colony-Stimulating Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D015994">Incidence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D007902">Length of Stay</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D009503">Neutropenia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D017410">Practice Guidelines as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D011994">Recombinant Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year>
<Month>12</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2013</Year>
<Month>12</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2015</Year>
<Month>9</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pii">46856</ArticleId>
<ArticleId IdType="pubmed">24320592</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000192 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000192 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Musique
   |area=    OperaV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:24320592
   |texte=   [OPERa Study].
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:24320592" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a OperaV1

This area was generated with Dilib version V0.6.21.
Data generation: Thu Apr 14 14:59:05 2016. Site generation: Thu Jan 4 23:09:23 2024

	Serveur d'exploration sur l'opéra
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur l'opéra

[OPERa Study].

[OPERa Study].

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki